17624-36-1

Basic information

• Product Name: 2-pyridyllithium
• Synonyms: 2-pyridyllithium;2-Lithiopyridine;Einecs 241-600-4
• CAS NO: 17624-36-1
• Molecular Formula: C₅H₄N*Li
• Molecular Weight: 85.03296
• EINECS: 241-600-4
• Mol File: 17624-36-1.mol

Chemical Properties

• Boiling Point: 115.3°Cat760mmHg
• Flash Point: 20°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 22.8mmHg at 25°C
• CAS DataBase Reference: 2-pyridyllithium(CAS DataBase Reference)
• NIST Chemistry Reference: 2-pyridyllithium(17624-36-1)
• EPA Substance Registry System: 2-pyridyllithium(17624-36-1)

Safety Data

• Hazardous Substances Data: 17624-36-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C5H4N.Li/c1-2-4-6-5-3-1;/h1-2,4-5H;/q-1;+1

Upstream product

• 109-04-6 2-bromo-pyridine 
• 109-72-8 n-butyllithium 

Downstream Products

• 54467-34-4 phenylbis(pyridine-2-yl)methanol 
• 101273-89-6 [2]Furyl-phenyl-[2]pyridyl-methanol 
• 19437-26-4 2,2'-dipyridyl ketone 
• 73569-80-9 tris(2-pyridyl)methyl alcohol 
• 107153-95-7 1-(4-chlorophenyl)-2-methyl-1-(2-pyridyl)-1-propanol 
• 103153-74-8 2-(1-phenyl-3-pyrrolidin-1-yl-propyl)-pyridine 
• 70708-25-7 1-phenyl-1-[2]pyridyl-3-pyrrolidino-propan-1-ol 
• 102008-18-4 2-(1-phenyl-3-piperidino-propyl)-pyridine 
• 64436-62-0 9-(pyridin-2-yl)-9H-fluoren-9-ol 
• 70708-26-8 1-[2]pyridyl-3-pyrrolidino-1-o-tolyl-propan-1-ol 
• 114254-86-3 2-[1-(4-chloro-phenyl)-3-pyrrolidin-1-yl-propyl]-pyridine 
• 102167-02-2 1-(4-ethyl-phenyl)-1-[2]pyridyl-3-pyrrolidino-propan-1-ol 
• 5897-97-2 <2>-Pyridylmercaptoacetaldehyd-dimethylacetal 
• 112868-04-9 1-(4-isopropyl-phenyl)-1-[2]pyridyl-3-pyrrolidino-propan-1-ol 

Relevant articles and documents

Synthesis, characterization, and crystal structures of tris(2-pyridyl) phosphine sulfide and selenide

We report the synthesis and structural determinations of tris(2-pyridyl)phosphine sulfide and selenide, which were prepared by the reaction of 2-lithiopyridine with phosphorus trichloride at -100°C, and treatment of resulted (2-pyridyl)phosphine with elemental sulfur or selenium in hot toluene. These compounds were characterized by elemental analysis, melting point determination, mass spectroscopy, IR, 1H, and 31P NMR spectroscopies. Furthermore, the molecular structures of tris(2-pyridyl)phosphine sulfide and selenide were determined by single crystal X-ray analysis and compared with the structures of tris(2-pyridyl)phosphine and tris(2-pyridyl)phosphine oxide. Copyright Taylor & Francis Group, LLC.

Ionic liquid, preparation method and application

The invention relates to an ionic liquid. Cations of the ionic liquid contain hexafluoroisopropyl sulfonic acid groups. According to the ionic liquid provided by the invention, the hexafluoroisopropylsulfonic acid groups are introduced into the cation part of the ionic liquid to give a super acid center to the ionic liquid, through changing anion types, the ionic liquid of which the acidity is greater than that of 98% concentrated sulfuric acid is obtained, and the highest level of the hamlet acidity (H0) in the obtained ionic liquid can reach -14.13.

Chemoselective Ketone Synthesis by the Addition of Organometallics to N-Acylazetidines

A general and highly chemoselective method for the synthesis of ketones by the addition of organometallics to N-acylazetidines via stable tetrahedral intermediates is reported for the first time. The transformation is characterized by its wide substrate scope and exquisite selectivity for the ketone products even when a large excess of nucleophilic reagents is used. Even of broader interest is the use of N-acylazetidines as bench-stable, readily available amide acylating reagents, in which the reactivity is controlled by amide pyramidalization and strain of the four-membered ring to afford synthetically valuable building blocks.

ORGANIC COMPOUNDS

The present invention relates to quinazolinone compounds of the formula wherein R2, R3, R5, R6 R7 and R8 are as defined in the specification and in the claims, in free form or in salt form , processes for their preparation and their use as pharmaceuticals, particularly in the treatment of disorders ameliorated by administration of TRPV1 antagonists.

Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists

Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M1 and M3 are CH or N; M2 is CH, CF or N; Y is —C(═O)—, —C(═S)—, —(CH2)q—, —C(═NOR7)— or —SO1-2—; Z is a bond or optionally substituted alkylene or alkenylene; R1 is H, alkyl, alkenyl, or optionally substituted cycloalkyl, aryl, heteroaryl, heterocycloalkyl or a group of the formula: where ring A is a monoheteroaryl ring; R1 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders using said compounds, alone or in combination with other agents.

IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF ANXIETY AND RELATED DISEASES

This invention relates to imidazole derivatives V of formula (I), pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAAreceptor complex, and in particular for combating anxiety and related diseases.

Sleep inducing compounds and methods relating thereto

Compounds having the following structure (I): including stereoisomers, prodrugs, and pharmaceutically acceptable salts, esters and solvates thereof, wherein R1, R2, R3a, R3b, L1, L2 and n are as defined herein. Such compounds generally function as H1 receptor ligands, and thus have utility as sleep inducing agents. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.

HETEROCYCLIC ANTI-MIGRAINE AGENTS

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

The 'inverse electron-demand' Diels-Alder reaction in polymer synthesis. Part 5: Preparation and model reactions of some electron-rich bis-dienamines

The m- and p-phenylene-bridged bis-azolopyridinium salts have been synthesized and converted into the corresponding bis-dienamines by reaction with pyrrolidine. These dienamines react readily with dimethyl 1,2,4,5-tetrazine-dicarboxylate to yield the bis-azolylvinyl-pyridazines.

Carbonylation catalyst system

A catalyst system, which comprises: a) a source of a Group VIII metal; b) a phosphine having an aromatic substituent which contains an imino nitrogen atom; c) a source of protons; and d) a tertiary amine.